# VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

Study · id `cardio:ct-nct06873321` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06873321](<https://clinicaltrials.gov/study/NCT06873321>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06873321

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Coronary and vascular disease; Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06873321. Randomized; single masking; primary purpose prevention. Start 2024-02-24 (actual); primary completion 2025-07-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06873321, source copy `cardio:ctgov-nct06873321-2025-03-12`, retrieved 2026-10-31)
- Started: 2024-02-24 (actual) (ClinicalTrials.gov record NCT06873321, source copy `cardio:ctgov-nct06873321-2025-03-12`, retrieved 2026-10-31)
- Primary completion: 2025-07-20 (anticipated) (ClinicalTrials.gov record NCT06873321, source copy `cardio:ctgov-nct06873321-2025-03-12`, retrieved 2026-10-31)
- Completion: 2025-07-30 (anticipated) (ClinicalTrials.gov record NCT06873321, source copy `cardio:ctgov-nct06873321-2025-03-12`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT06873321, source copy `cardio:ctgov-nct06873321-2025-03-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06873321-2025-03-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
- Acronym: RESOLUTION
- Condition: Peripheral Arterial Disease
- Condition: Venous Thormboembolism
- Condition: Cardiovascular Diseases
- Condition: Vascular Surgery Patient with PAD / Carotid Stenosis
- Intervention (Drug): rivaroxaban 2.5 mg bid + aspirin 100 mg
- Intervention (Drug): clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
- Lead sponsor: Science Valley Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 616175b659a728c38accf7c651d6c0c9cb02376b097f1b87fb2131113aa42e0f
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
